Literature DB >> 8453619

Chronopharmacology of high-dose busulfan in children.

G Vassal1, D Challine, S Koscielny, O Hartmann, A Deroussent, I Boland, D Valteau-Couanet, J Lemerle, F Lévi, A Gouyette.   

Abstract

In bone marrow transplantation, high-dose busulfan is given p.o., usually every 6 h over 4 consecutive days. Since this repeated administration might alter busulfan disposition, fluctuations in busulfan plasma levels were studied over the 4-day treatment period in 21 children (median age, 5 years) with malignant solid tumors. In addition, urinary excretion of unchanged busulfan was measured every 6 h in 4 patients. Busulfan (37.5 mg/m2 for 16 doses) was given on an empty stomach at 12 p.m., 6 p.m., midnight, and 6 a.m. for 4 consecutive days, starting at 12 p.m. Trough plasma levels, i.e., concentration 6 h after each dose and just before the next one, and urinary excretion of busulfan were measured using a gas chromatography-mass spectrometry assay. Busulfan trough plasma levels exhibited a significant circadian rhythm with a higher mean level at 6 a.m. compared to that at 12 p.m., 6 p.m., and midnight. This rhythm was characterized by a double amplitude (mean +/- SD) of 42 +/- 14% and an acrophase (maximum) occurring at 5:48 a.m. +/- 115 min. In addition, once the steady state was reached, no decreasing trend was observed in any patient. Busulfan renal clearance proved to be low since only 5.4 +/- 1.2% of the given dose were excreted unchanged in urine. In the 4 patients studied, busulfan urinary excretion exhibited a significant circadian rhythm which was apparently linked to the physiological circadian rhythm in urinary output. Ten of 20 evaluable patients developed hepatic venoocclusive disease (HVOD). A significant circadian rhythm in the plasma level was found in both HVOD and non-HVOD patients with no difference between the two groups with regard to the 24-h mean, amplitude, or acrophase. Thus, the circadian changes in busulfan trough plasma levels observed at the steady state were not related to the occurrence of HVOD in these children with solid tumors. Moreover, since this rhythm was stable from day 2 to day 4, it should not compromise dose adjustment.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8453619

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  Will high dose chemotherapy followed by autologous bone marrow transplantation supplant cranio-spinal irradiation in young children treated for medulloblastoma?

Authors:  S Dupuis-Girod; O Hartmann; E Benhamou; F Doz; F Mechinaud; E Bouffet; C Coze; C Kalifa
Journal:  J Neurooncol       Date:  1996-01       Impact factor: 4.130

2.  Test Dose Pharmacokinetics in Pediatric Patients Receiving Once-Daily IV Busulfan Conditioning for Hematopoietic Stem Cell Transplant: A Reliable Approach?

Authors:  Kristina M Brooks; Paul Jarosinski; Thomas Hughes; Elizabeth Kang; Nirali N Shah; John B Le Gall; Dennis D Hickstein; Suk See De Ravin; Jomy M George; Parag Kumar
Journal:  J Clin Pharmacol       Date:  2017-12-14       Impact factor: 3.126

Review 3.  The role of busulfan in bone marrow transplantation.

Authors:  M Hassan
Journal:  Med Oncol       Date:  1999-09       Impact factor: 3.064

4.  Exposure equivalence between IV (0.8 mg/kg) and oral (1 mg/kg) busulfan in adult patients.

Authors:  F Léger; L Nguyen; C Puozzo
Journal:  Eur J Clin Pharmacol       Date:  2009-05-08       Impact factor: 2.953

5.  Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103).

Authors:  Jan H Beumer; Kouros Owzar; Lionel D Lewis; Chen Jiang; Julianne L Holleran; Susan M Christner; William Blum; Steven Devine; Jonathan E Kolitz; Charles Linker; Ravi Vij; Edwin P Alyea; Richard A Larson; Mark J Ratain; Merrill J Egorin
Journal:  Cancer Chemother Pharmacol       Date:  2014-08-28       Impact factor: 3.333

6.  Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics.

Authors:  M Hassan; G Oberg; M Björkholm; I Wallin; M Lindgren
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 7.  Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review.

Authors:  Alan L Myers; Jitesh D Kawedia; Richard E Champlin; Mark A Kramer; Yago Nieto; Romi Ghose; Borje S Andersson
Journal:  Expert Opin Drug Metab Toxicol       Date:  2017-08-17       Impact factor: 4.481

8.  Busulphan is active against neuroblastoma and medulloblastoma xenografts in athymic mice at clinically achievable plasma drug concentrations.

Authors:  I Boland; G Vassal; J Morizet; M J Terrier-Lacombe; D Valteau-Couanet; C Kalifa; O Hartmann; A Gouyette
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

9.  Multiple Integrated Non-clinical Studies Predict the Safety of Lentivirus-Mediated Gene Therapy for β-Thalassemia.

Authors:  Maria Rosa Lidonnici; Ylenia Paleari; Francesca Tiboni; Giacomo Mandelli; Claudia Rossi; Michela Vezzoli; Annamaria Aprile; Carsten Werner Lederer; Alessandro Ambrosi; Franck Chanut; Francesca Sanvito; Andrea Calabria; Valentina Poletti; Fulvio Mavilio; Eugenio Montini; Luigi Naldini; Patrizia Cristofori; Giuliana Ferrari
Journal:  Mol Ther Methods Clin Dev       Date:  2018-09-13       Impact factor: 6.698

10.  Pooled population pharmacokinetic analysis of phase I, II and III studies of linifanib in cancer patients.

Authors:  Ahmed Hamed Salem; Denise Koenig; Dawn Carlson
Journal:  Clin Pharmacokinet       Date:  2014-04       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.